Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in Patients With Metastatic Melanoma

Trial Profile

Study of GSK2302025A Antigen-Specific Cancer Immunotherapeutic in Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2017

At a glance

  • Drugs GSK 2302025A (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
  • Acronyms PRAME-AS15-MEL001
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 02 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 04 Feb 2017 This trial was completed in Czech Republic (end date:19 Dec 2016).
    • 07 Aug 2015 Planned End Date changed from 1 Jan 2018 to 1 Dec 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top